Kymera Therapeutics Inc (NAS:KYMR)
$ 35.32 -0.69 (-1.92%) Market Cap: 2.17 Bil Enterprise Value: 1.78 Bil PE Ratio: 0 PB Ratio: 3.11 GF Score: 60/100

Kymera Therapeutics Inc at Bank of America Healthcare Conference Transcript

May 12, 2022 / 03:00PM GMT
Release Date Price: $16.9 (+1.81%)
Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst

Good morning. Welcome to the third day of the Bank of America Healthcare Conference. My name is Geoff Meacham, I'm the Senior Biopharma Analyst here. And we're really excited today to have Kymera Therapeutics. Speaking on behalf of Kymera is the CEO, Nello Mainolfi. And we're going to do like a 5-minute or so presentation and then we'll do a Q&A afterwards. Nello?

Nello Mainolfi
Kymera Therapeutics, Inc. - Co-Founder, President, CEO & Director

Thanks, Geoff. Thanks for the invite and the opportunity to present. We just have a few slides of introduction, just to set the stage for the Q&A that we'll have in a few minutes. Just to remind everybody, Kymera was founded now almost 6 years ago with the goal of building a fully integrated biotech that will be able to take targeted protein degradation from an early technology into a commercial stage reality. The platform is obviously disease agnostic. The platform is also target type agnostic. We had decided early on to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot